Insulin sensitive and resistant obesity in humans: AMPK activity, oxidative stress, and depot-specific changes in gene expression in adipose tissue

Journal of Lipid Research

Volumn 53, Issue 4, 2012, Pages 792-801

  Xu, X Julia ^a   Gauthier, Marie Soleil ^a   Hess, Donald T ^a   Apovian, Caroline M ^a   Cacicedo, Jose M ^a   Gokce, Noyan ^a   Farb, Melissa ^a   Valentine, Rudy J ^a   Ruderman, Neil B ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adenosine monophosphate activated protein kinase; Inflammation; Insulin sensitivity

Indexed keywords

ANGIOTENSINOGEN; ANTIDEPRESSANT AGENT; CARBONYL DERIVATIVE; CD4 ANTIGEN; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MESSENGER RNA; METFORMIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN A;

ABDOMINAL SUBCUTANEOUS FAT; ADIPOSE TISSUE; ADULT; ANATOMICAL VARIATION; ARTICLE; BARIATRIC SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION PROFILING; HOMEOSTASIS; HUMAN; HUMAN TISSUE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; MORBID OBESITY; OUTCOME ASSESSMENT; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN ISOLATION; ROUX Y ANASTOMOSIS;

ADENYLATE KINASE; ADIPOSE TISSUE; ADULT; ANGIOTENSINOGEN; BODY MASS INDEX; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HOMEOSTASIS; HUMANS; INFLAMMATION; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; OBESITY, MORBID; OXIDATIVE STRESS; PHOSPHORYLATION; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84859412650     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P022905     Document Type: Article

References (63)

1. Klöting, N., M. Fasshauer, A. Dietrich, P. Kovacs, M. R. Schon, M. Kern, M. Sutumvoll, and M. Blüher. 2010. Insulin-sensitive obesity. Am. J. Physiol. Endocrinol. Metab. 299: E506-E515.
2. Sims, E. A. 2001. Are there persons who are obese, but metabolically healthy? Metabolism. 50: 1499-1504. (Pubitemid 34007425)
3. Reaven, G. 2005. All obese individuals are not created equal: insulin resistance is the major determinant of cardiovascular disease in overweight/obese individuals. Diab. Vasc. Dis. Res. 2: 105-112. (Pubitemid 41695168)
4. Stefan, N., K. Kantartzis, J. Machann, F. Schick, C. Thamer, K.Rittig, B. Balletshofer, F. Machicao, A. Fritsche, and H. U. Häring. 2008. Identification and characterization of metabolically benign obesity in humans. Arch. Intern. Med. 168: 1609-1616.
5. Gauthier, M. S., and N. B. Ruderman. 2010. Adipose tissue inflammation and insulin resistance: all obese humans are not created equal. Biochem. J. 430: e1-e4.
6. Ferrannini, E., A. Natali, P. Bell, P. Cavallo-Perin, N. Lalic and G. Ningrone. 1997. Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J. Clin. Invest. 100: 1166-1173.
7. Bogardus, C., S. Lillioja, D. M. Mott, C. Hollenbeck, and G. Reaven. 1985. Relationship between degree of obesity and in vivo insulin action in man. Am. J. Physiol. 248: E286-E291. (Pubitemid 15076590)
8. Gauthier, M-S., E. L. O'Brien, S. Bigornia, M. Mott, J. M. Cacicedo, X. J. Xu, N. Gokce, C. Apovian, and N. Ruderman. 2011. Decreased AMP-activated protein kinase activity is associated with increased inflammation in visceral adipose tissue and with whole-body insulin resistance in morbidly obese humans. Biochem. Biophys. Res. Commun. 404: 382-387.
9. Bergeron, R., S. F. Previs, G. W. Cline, P. Perret, R. R. Russell 3rd, L. H. Young, and G. I. Shulman. 2001. Effect of 5-aminoimidazole-4-carboxamide- 1-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. Diabetes. 50: 1076-1082. (Pubitemid 32374538)
10. Fisher, J. S., J. Gao, D. H. Han, J. O. Holloszy, and L. A. Nolte. 2002. Activation of AMP kinase enhances sensitivity of muscle glucose transport to insulin. Am. J. Physiol. Endocrinol. Metab. 282: E18-E23. (Pubitemid 34654101)
11. Iglesias, M. A., J. M. Ye, G. Frangioudakis, A. K. Saha, E. Tomas, N. B. Ruderman, G. J. Cooney, and E. W. Kraegen. 2002. AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats. Diabetes. 51: 2886-2894.
12. Ruderman, N., and M. Prentki. 2004. AMP kinase and malonyl- CoA: targets for therapy of the metabolic syndrome. Nat. Rev. Drug Discov. 3: 340-351. (Pubitemid 38499761)
13. Bandyopadhyay, G. K., J. G. Yu, J. Ofrecio, and J. M. Olefsky. 2006. Increased malonyl-CoA levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis. Diabetes. 55: 2277-2285. (Pubitemid 44743625)
14. Sriwijitkamol, A., D. K. Coletta, E. Wajcberg, G. B. Balbontin, S. M. Reyna, J. Barrientes, P. A. Eagan, C. P. Jenkinson, E. Cersosimo, R. A. DeFronzo, K. Sakamoto, and N. Musi. 2007. Effect of acute exercise on AMPK signaling in skeletal muscle of subjects with type 2 diabetes: a time-course and dose-response study. Diabetes. 56: 836-848. (Pubitemid 46348486)
15. Højlund, K., K. J. Mustard, P. Staehr, D. G. Hardie, H. Beck-Nielsen, E. A. Richter, and J. F. Wojtaszewski. 2004. AMPK activity and isoform protein expression are similar in muscle of obese subjects with and without type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 286: E239-E244. (Pubitemid 38140315)
16. Kola, B., M. Christ-Crain, F. Lolli, G. Arnaldi, G. Giacchetti, M. Boscaro, A. B. Grossman, and M. Korbontis. 2008. Changes in adenosine 5′-monophosphate-activated protein kinase as a mechanism of visceral obesity in Cushing's syndrome. J. Clin. Endocrinol. Metab. 93: 4969-4973.
17. Wellen, K. E., and G. S. Hotamisligil. 2005. Inflammation, stress, and diabetes. J. Clin. Invest. 115: 1111-1119. (Pubitemid 40629025)
18. Barbarroja, N., R. Lopez-Pedrera, M. D. Mayas, E. Garcia-Fuentes, L. Garrido-Sánchez, M. Macías-González, R. El Bekay, A. Vidal-Puig, and F. J. Tinahones. 2010. The obese healthy paradox: is inflammation the answer? Biochem. J. 430: 141-149.
19. Block, G., M. Dietrich, E. P. Norkus, J. D. Morrow, M. Hudes, B. Caan, and L. Packer. 2002. Factors associated with oxidative stress in human populations. Am. J. Epidemiol. 156: 274-285. (Pubitemid 34810481)
20. Olusi, S. O. 2002. Obesity is an independent risk factor for plasma lipid peroxidation and depletion of erythrocyte cytoprotectic enzymes in humans. Int. J. Obes.Relat. Metab. Disord. 26: 1159-1164.
21. Uzun, H., D. Konukoglu, R. Gelisgen, K. Zemgin, and T. Mustafa. 2007. Plasma protein carbonyl and thiol stress before and after laparascopic gastric banding in morbidly obese patients. Obes. Surg. 17: 1367-1373.
22. Tadros, T. M., J. M. Massaro, G. A. Rosito, U. Hoffmann, et al. 2010. Pericardial fat volume correlates with inflammatory markers: the Framingham Heart Study. Obesity (Silver Spring). 18: 1039-1045.
23. Furukawa, S., T. Fujita, M. Shimabukuro, M. Iwaki, Y. Yamada, Y. Nakajima, O. Nakayama, M. Makishima, M. Matsuda, and I. Shimomura. 2004. Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest. 114: 1752-1761. (Pubitemid 40385531)
24. Ceriello, A., and E. Motz. 2004. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler. Thromb. Vasc. Biol. 24: 816-823. (Pubitemid 38620857)
25. Houstis, N., E. D. Rosen, and E. S. Lander. 2006. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature. 440: 944-948.
26. Brownlee, M. 2001. Biochemistry and molecular cell biology of diabetic complications. Nature. 414: 813-820. (Pubitemid 34000785)
27. Matthews, D. R., J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher, and R. C. Turner. 1985. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28: 412-419. (Pubitemid 15018832)
28. Livak, K. J., and T. D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25: 402-408. (Pubitemid 34164012)
29. Grundy, S. M., J. I. Cleeman, S. R. Daniels, et al. 2005. Diagnosis and management of the metabolic syndrome: an AHA/NHLBI scientifi c statement. Circulation. 112: 2735-2752.
30. Hawley, S. A., M. Davison, A. Woods, S. P. Davies, R. K. Beri, D. Carling, and D. G. Hardie. 1996. Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. J. Biol. Chem. 271: 27879-27887. (Pubitemid 26367365)
31. Cooper, R., T. Forrester, O. Ogunbiyi, and J. J. Muffinda. 1998. Angiotensinogen levels and obesity in four black populations. ICSHIB Investigators. J. Hypertens. 16: 571-575. (Pubitemid 28230544)
32. Burns, A. R., R. A. Bowden, Y. Abe, D. C. Walker, S. I. Simon, et al. 1999. P-selectin mediates neutrophil adhesion to endothelial cell borders. J. Leukoc. Biol. 65: 299-306. (Pubitemid 29109700)
33. Cantó, C., Z. Gerhart-Hines, J. N. Feige, M. Lagouge, L. Noriega, J. C. Milne, P. J. Elliott, P. Puigserver, and J. Auwerx. 2009. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature. 458: 1056-1060.
34. McGillicuddy, F. C., E. H. Chiguoine, C. C. Hinkle, R. J. Kim, R. Shah, H. M. Roche, E. M. Smyth, and M. P. Reilly. 2009. Interferon gamma attenuates insulin signaling, lipid storage, and differentiation in human adipocytes via activation of the JAK/STAT pathway. J. Biol. Chem. 284: 31936-31944.
35. Kola, B., A. B. Grossman, and M. Korbonits. 2008. The role of AMP-activated protein kinase in obesity. Front. Horm. Res. 36: 198-211.
36. Yang, H., S. Lavu, and D. A. Sinclair. 2006. Nampt/PBEF/Visfatin: a regulator of mammalian health and longevity? Exp. Gerontol. 41: 718-726. (Pubitemid 44223900)
37. Wajchenberg, B. L. 2000. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr. Rev. 21: 697-738. (Pubitemid 32113289)
38. Hellmér, J., C. Marcus, T. Sonnenfeld, and P. Arner. 1992. Mechanisms for differences in lipolysis between human subcutaneous and omental fat cells. J. Clin. Endocrinol. Metab. 75: 15-20.
39. Joe, A. W. B., L. Yi, Y. Even, A. W. Vogl, and F. M. V. Rossi. 2009. Depot-specific differences in adipogenic progenitor abundance and proliferative response to high-fat diet. Stem Cells. 27: 2563-2570.
40. Vidal-Puig, A., M. Jimenez-Linan, B. B. Lowell, A. Hamann, E. Hu, B. Spiegelman, J. S. Flier, and D. E. Moller. 1996. Regulation of PPARg Gene Expression by Nutrition and Obesity in Rodents. J. Clin. Invest. 97: 2553-2561. (Pubitemid 26187343)
41. Ferder, L., F. Inserra, and M. Martinez-Maldonado. 2006. Inflammation and the metabolic syndrome: role of angiotensin II and oxidative stress. Curr. Hypertens. Rep. 8: 191-198. (Pubitemid 43853445)
42. Elchebly, M., P. Payette, E. Michaliszyn, W. Cromlish, S. Collins, A. L. Loy, D. Normandin, A. Cheng, J. Himms-Hagen, C. C. Chan, et al. 1999. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science. 283: 1544-1548.
43. Tschritter, O., A. Fritsche, C. Thamer, M. Haap, C. Thamer, O. Bachmann, D. Dahl, E. Maerker, A. Teigeler, F. Machicao, et al. 2003. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes. 52: 239-243. (Pubitemid 36173174)
44. Alessi, M. C., M. Poggi, and I. Juhan-Vague. 2007. Plasminogen activator inhibitor-1, adipose tissue and insulin resistance. Curr. Opin. Lipidol. 18: 240-245. (Pubitemid 46743045)
45. Daval, M., F. Diot-Dupuy, R. Bazin, I. Hainault, B. Viollet, S. Vaulont, E. Hajduch, P. Ferré, and F. Foufelle. 2005. Anti-lipolytic action of AMP-activated protein kinase in rodent adipocytes. J. Biol. Chem. 280: 25250-25257. (Pubitemid 40934619)
46. Yang, Z., B. B. Kahn, H. Shi, and B. Z. Xue. 2010. Macrophage alph1 AMP-activated protein kinase (alpha1AMPK) antagonizes fatty acid-induced inflammation through SIRT1. J. Biol. Chem. 285: 19051-19059.
47. Colombo, S. L., and S. Moncada. 2009. AMPKα1 regulates the antioxidant status of vascular endothelial cells. Biochem. J. 421: 163-169.
48. Morizane, Y., A. Thanos, K. Takeuchi, Y. Murakami, M. Kayama, G. Trichonas, J. Miller, M. Foretz, B. Viollet, and D. G. Vavvas. 2011. AMP-activated protein kinase suppresses matrix metalloproteinase- 9 expression in mouse embryonic fibroblasts. J. Biol. Chem. 286: 16030-16038.
49. Boyle, J. G., P. J. Logan, G. C. Jones, M. Small, N. Sattar, J. M. Connell, S. J. Cleland, and I. P. Salt. 2011. AMP-activated protein kinase is activated in adipose tissue of individuals with type 2 diabetes treated with metformin: a randomised glycaemia-controlled crossover study. Diabetologia. 54: 1799-1809.
50. Davies, K. J. 1987. Protein damage and degradation by oxygen radicals. J. Biol. Chem. 262: 9895-9901.
51. Frohnert, B., A. R. Sinaiko, F. J. Serrot, R. E. Foncea, A. Moran, S. Ikramuddin, U. Choudry, and D. A. Bernlohr. 2011. Increased adipose protein carbonylation in human obesity. Obesity (Silver Spring). 19: 1735-1741.
52. Gletsu-Miller, N., J. M. Hansen, D. P. Jones, Y-M. Go, W. E. Torres, T. R. Ziegler, and E. Lin. 2009. Loss of total and visceral adipose tissue mass predicts decreases in oxidative stress after weight-loss surgery. Obesity (Silver Spring). 17: 439-446.
53. Yang, H., T. Yang, J. A. Baur, E. Perez, T. Matsui, J. J. Carmona, D. W. Lamming, N. C. Souza-Pinto, V. A. Bohr, A. Rosenzweig, et al. 2007. Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell. 130: 1095-1107. (Pubitemid 47410271)
54. Rongvaux, A., M. Galli, S. Denanglaire, F. Van Gool, P. L. Dreze, C. Szpirer, F. Bureau, F. Andris, and O. Leo. 2008. Nicotinamide phosphoribosyl transferase/pre-B cell colony-enhancing factor/visfatin is required for lymphocyte development and cellular resistance to genotoxic stress. J. Immunol. 181: 4685-4695.
55. Ruderman, N. B., J. X. Xu, L. E. Nelson, J. M. Cacicedo, A. K. Saha, F. Lan, and Y. Ido. 2010. AMPK and SIRT1: a long-standing partnership? Am. J. Physiol. Endocrinol. Metab. 298: E751-E760.
56. Fulco, M., Y. Cen, P. Zhao, E. P. Hoffman, M. W. McBurney, A. A. Sauve, and V. Sartorelli. 2008. Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPKmediated regulation of Nampt. Dev. Cell. 14: 661-673. (Pubitemid 351622608)
57. Costa, C. S., T. O. Hammes, F. Rohden, R. Margis, J. W. Bortolotto, A. V. Padoin, C. C. Mottin, and R. M. Guaragna. 2010. SIRT1 transcription is decreased in visceral adipose tissue of morbidly obese patients with severe hepatic steatosis. Obes. Surg. 20: 633-639.
58. Gauthier, M. S., H. Miyoshi, S. C. Souza, J. M. Cacicedo, A. K. Saha, A. S. Greenberg, and N. B. Ruderman. 2008. AMP-activated protein kinase is activated as a consequence of lipolysis in the adipocyte: potential mechanism and physiological relevance. J. Biol. Chem. 283: 16514-16524.
59. Cacicedo, J. M., N. Yagihashi, J. F. Keaney Jr, N. B. Ruderman, and Y. Ido. 2004. AMPK inhibits fatty acid-induced increases in NF-kB transactivation in cultured human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun. 324: 1204-1209. (Pubitemid 40292150)
60. Sag, D., D. Carling, R. D. Stout, and J. Suttles. 2008. Adenosine 5′-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. J. Immunol. 181: 8633-8641.
61. Steinberg, G. R., B. J. Michell, B. J. W. van Denderen, M. J. Watt, A. L. Carey, B. C. Fam, S. Andrikopoulos, J. Proietto, C. Z. Görgün, D. Carling, et al. 2006. Tumor necrosis factor a-induced skeletal muscle insulin resistance involves suppression of AMP-kinase signaling. Cell Metab. 4: 465-474. (Pubitemid 44834113)
62. Wu, Y., P. Song, J. Xu, M. Zhang, and M-H. Zou. 2007. Activation of protein phosphatase 2a by palmitate inhibits AMP-activated protein kinase. J. Biol. Chem. 282: 9777-9788. (Pubitemid 47104626)
63. Hummasti, S., and G. S. Hotamisligil. 2010. Endoplasmic reticulum stress and inflammation in obesity and diabetes. Circ. Res. 107: 579-591.